Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Rapt Therapeutics price target raised to $51 from $37 at Cantor Fitzgerald » 06:54
07/27/20
07/27
06:54
07/27/20
06:54
RAPT

Rapt Therapeutics

$21.92 /

-3.22 (-12.81%)

Cantor Fitzgerald analyst…

Cantor Fitzgerald analyst Altheia Young raised the firm's price target on Rapt Therapeutics to $51 from $37 and keeps an Overweight rating on the shares. Ahead of the company's proof-of-concept data for both of its CCR4 programs in 2H, Young says Rapt is a highly underappreciated story with two big catalysts expected by year end. The analyst believes this is a stock with significant upside potential and relatively low investor awareness given it has two distinct near-term "shots on goal" with proof-of-concept readouts in oncology and atopic dermatitis and believes either opportunity represents a large enough market to be a blockbuster drug, even if the other "shot on goal" does not play out.

ShowHide Related Items >><<
RAPT Rapt Therapeutics
$21.92 /

-3.22 (-12.81%)

RAPT Rapt Therapeutics
$21.92 /

-3.22 (-12.81%)

07/13/20 Wells Fargo
Rapt Therapeutics price target raised to $40 from $33 at Wells Fargo
06/01/20 H.C. Wainwright
Rapt Therapeutics initiated with a Buy at H.C. Wainwright
05/19/20
Fly Intel: Top five analyst initiations
05/19/20 Roth Capital
Rapt CCR4 antagonist may be competitive against Dupixent, says Roth Capital
RAPT Rapt Therapeutics
$21.92 /

-3.22 (-12.81%)

  • 07
    Feb
  • 31
    Oct
Recommendations
Rapt Therapeutics price target raised to $40 from $33 at Wells Fargo » 09:07
07/13/20
07/13
09:07
07/13/20
09:07
RAPT

Rapt Therapeutics

$25.48 /

-0.88 (-3.34%)

Wells Fargo analyst Yanan…

Wells Fargo analyst Yanan Zhu raised the firm's price target on Rapt Therapeutics to $40 from $33 and keeps an Overweight rating on the shares following his FLX475-focused update call with management. The analyst cites increased probability of success for the FLX475 program in charged tumors. Overall, while Zhu continues to see the allergic inflammatory disease product candidate RPT193 as the major value driver for RAPT, the analyst now also views the prospects of the FLX475 cancer program as increasingly favorable as the ongoing phase 1/2 study progresses toward proof-of-concept data readout across eight phase 2 cohorts the second half of 2020.

ShowHide Related Items >><<
RAPT Rapt Therapeutics
$25.48 /

-0.88 (-3.34%)

RAPT Rapt Therapeutics
$25.48 /

-0.88 (-3.34%)

06/01/20 H.C. Wainwright
Rapt Therapeutics initiated with a Buy at H.C. Wainwright
05/19/20
Fly Intel: Top five analyst initiations
05/19/20 Roth Capital
Rapt CCR4 antagonist may be competitive against Dupixent, says Roth Capital
05/18/20 Cantor Fitzgerald
Rapt Therapeutics initiated with an Overweight at Cantor Fitzgerald
RAPT Rapt Therapeutics
$25.48 /

-0.88 (-3.34%)

  • 07
    Feb
  • 31
    Oct
Over a month ago
Initiation
Rapt Therapeutics initiated with a Buy at H.C. Wainwright » 06:25
06/01/20
06/01
06:25
06/01/20
06:25
RAPT

Rapt Therapeutics

$18.26 /

+0.75 (+4.28%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Raghuram Selvaraju initiated coverage of Rapt Therapeutics with a Buy rating and $40 price target. The company has hit upon a novel way to address immune system dysregulation in both allergic disorders and cancer, Selvaraju tells investors in a research note. The analyst sees multiple near- and medium-term catalysts for the shares.

ShowHide Related Items >><<
RAPT Rapt Therapeutics
$18.26 /

+0.75 (+4.28%)

RAPT Rapt Therapeutics
$18.26 /

+0.75 (+4.28%)

05/19/20
Fly Intel: Top five analyst initiations
05/19/20 Roth Capital
Rapt CCR4 antagonist may be competitive against Dupixent, says Roth Capital
05/18/20 Cantor Fitzgerald
Rapt Therapeutics initiated with an Overweight at Cantor Fitzgerald
04/13/20
Fly Intel: Top five analyst initiations
RAPT Rapt Therapeutics
$18.26 /

+0.75 (+4.28%)

Hot Stocks
Rapt Therapeutics announces poster presentation for Phase 1/2 trial of FLX475 » 08:30
05/29/20
05/29
08:30
05/29/20
08:30
RAPT

Rapt Therapeutics

$17.51 /

-0.5 (-2.78%)

RAPT Therapeutics…

RAPT Therapeutics announced the presentation of a Trials in Progress poster for the ongoing seamless Phase 1/2 clinical trial of FLX475, a small molecule CCR4 antagonist in development for multiple tumor types. The poster was presented at the American Society of Clinical Oncology 2020. The poster presentation detailed previously reported initial Phase 1 healthy volunteer data for FLX475 that demonstrated excellent safety, pharmacokinetics and target engagement. FLX475 is designed to block regulatory T cells from migrating to tumor sites, where they suppress immune system responses to cancer cells, without depleting regulatory T cells in the rest of the body nor immune cells required for an anti-tumor response. A robust pharmacodynamic assay measuring receptor occupancy on circulating regulatory T cells demonstrated that FLX475 achieved exposure levels over the targeted 75%, predicting maximal inhibition of regulatory T cell recruitment into tumors via CCR4 signaling. In addition, levels of FLX475 increased in a dose-proportional manner, with a strong PK/PD correlation observed between drug levels and receptor occupancy. Building on these data, RAPT initiated a seamless Phase 1/2 study of FLX475. The Phase 1 portion of the trial was a standard dose escalation study in patients with many types of cancer, and the Phase 2 portion is evaluating FLX475 both as monotherapy and in combination with a checkpoint inhibitor in patients with "charged" tumors, which are tumors that express high levels of CCR4 ligands, and have a high presence of regulatory T cells and CD8+ effector T cells. RAPT is currently enrolling the Phase 2 portion of the trial in patients with charged tumors, including non-small cell lung cancer, triple negative breast cancer, head and neck squamous cell carcinoma, cervical cancer as well as EBV-positive nasopharyngeal cancer and lymphomas.

ShowHide Related Items >><<
RAPT Rapt Therapeutics
$17.51 /

-0.5 (-2.78%)

RAPT Rapt Therapeutics
$17.51 /

-0.5 (-2.78%)

05/19/20
Fly Intel: Top five analyst initiations
05/19/20 Roth Capital
Rapt CCR4 antagonist may be competitive against Dupixent, says Roth Capital
05/18/20 Cantor Fitzgerald
Rapt Therapeutics initiated with an Overweight at Cantor Fitzgerald
04/13/20
Fly Intel: Top five analyst initiations
RAPT Rapt Therapeutics
$17.51 /

-0.5 (-2.78%)

Initiation
Fly Intel: Top five analyst initiations » 10:11
05/19/20
05/19
10:11
05/19/20
10:11
BYND

Beyond Meat

$139.44 /

+9.44 (+7.26%)

, RAPT

Rapt Therapeutics

$17.88 /

+1.56 (+9.56%)

, OSPN

OneSpan

$18.56 /

+0.25 (+1.37%)

, DKNG

DraftKings

$28.60 /

-0.96 (-3.25%)

, ORIC

ORIC Pharmaceuticals

$32.19 /

+0.27 (+0.85%)

Catch up on today's…

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Beyond Meat (BYND) initiated with a Buy at BTIG. 2. Rapt Therapeutics (RAPT) initiated with an Overweight at Cantor Fitzgerald. 3. OneSpan (OSPN) initiated with a Buy at Needham. 4. DraftKings (DKNG) initiated with a Neutral at Goldman Sachs. 5. ORIC Pharmaceuticals (ORIC) initiated with an Overweight at JPMorgan, a Buy at Jefferies and Guggenheim, and a Neutral at Citi. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
RAPT Rapt Therapeutics
$17.88 /

+1.56 (+9.56%)

OSPN OneSpan
$18.56 /

+0.25 (+1.37%)

ORIC ORIC Pharmaceuticals
$32.19 /

+0.27 (+0.85%)

DKNG DraftKings
$28.60 /

-0.96 (-3.25%)

BYND Beyond Meat
$139.44 /

+9.44 (+7.26%)

BYND Beyond Meat
$139.44 /

+9.44 (+7.26%)

05/18/20 BTIG
Beyond Meat started with a Buy at BTIG on potential partnerships major chains
05/18/20 BTIG
Beyond Meat initiated with a Buy at BTIG
05/06/20 Goldman Sachs
Goldman Sachs reduces 2020-22 revenue estimates for Beyond Meat after Q1 report
05/06/20 DA Davidson
Beyond Meat price target raised to $83 from $62 at DA Davidson
RAPT Rapt Therapeutics
$17.88 /

+1.56 (+9.56%)

05/19/20 Roth Capital
Rapt CCR4 antagonist may be competitive against Dupixent, says Roth Capital
05/18/20 Cantor Fitzgerald
Rapt Therapeutics initiated with an Overweight at Cantor Fitzgerald
04/13/20
Fly Intel: Top five analyst initiations
04/13/20 Roth Capital
Rapt Therapeutics initiated with a Buy at Roth Capital
OSPN OneSpan
$18.56 /

+0.25 (+1.37%)

05/19/20 Needham
OneSpan initiated with a Buy at Needham
05/18/20 Needham
OneSpan initiated with a Buy at Needham
03/27/20 BTIG
OneSpan assumed with a Neutral at BTIG
06/25/19 B. Riley FBR
OneSpan initiated with a Buy at B. Riley FBR
DKNG DraftKings
$28.60 /

-0.96 (-3.25%)

05/19/20 Goldman Sachs
DraftKings initiated with a Neutral at Goldman Sachs
05/18/20 Craig-Hallum
DraftKings price target raised to $35 from $30 at Craig-Hallum
05/18/20 Northland
DraftKings price target raised to $33 from $24 at Northland
05/15/20 Canaccord
DraftKings price target raised to $35 from $25 at Canaccord
ORIC ORIC Pharmaceuticals
$32.19 /

+0.27 (+0.85%)

05/19/20 JPMorgan
ORIC Pharmaceuticals initiated with an Overweight at JPMorgan
05/19/20 Guggenheim
Guggenheim starts ORIC Pharmaceuticals at Buy with $45 price target
05/19/20 Jefferies
ORIC Pharmaceuticals initiated with a Buy at Jefferies
05/19/20 Citi
ORIC Pharmaceuticals initiated with a Neutral at Citi
RAPT Rapt Therapeutics
$17.88 /

+1.56 (+9.56%)

OSPN OneSpan
$18.56 /

+0.25 (+1.37%)

DKNG DraftKings
$28.60 /

-0.96 (-3.25%)

BYND Beyond Meat
$139.44 /

+9.44 (+7.26%)

BYND Beyond Meat
$139.44 /

+9.44 (+7.26%)

OSPN OneSpan
$18.56 /

+0.25 (+1.37%)

ORIC ORIC Pharmaceuticals
$32.19 /

+0.27 (+0.85%)

DKNG DraftKings
$28.60 /

-0.96 (-3.25%)

BYND Beyond Meat
$139.44 /

+9.44 (+7.26%)

DKNG DraftKings
$28.60 /

-0.96 (-3.25%)

BYND Beyond Meat
$139.44 /

+9.44 (+7.26%)

Recommendations
Rapt CCR4 antagonist may be competitive against Dupixent, says Roth Capital » 09:46
05/19/20
05/19
09:46
05/19/20
09:46
RAPT

Rapt Therapeutics

$17.00 /

+0.68 (+4.17%)

, REGN

Regeneron

$559.60 /

+0.23 (+0.04%)

Rapt Therapeutics (RAPT),…

Rapt Therapeutics (RAPT), at the Society for Investigative Dermatology virtual meeting, presented updated preclinical data and Phase 1a safety/PK-PD data in healthy-volunteers for RPT193, its orally-available CCR4 antagonist, that provided further evidence of its competitive safety and tolerability, Roth Capital analyst Zegbeh Jallah tells investors in a research note. The analyst continues to believe RPT193 could be competitive to Regeneron's (REGN) blockbuster Dupixent and expects the Phase 1b data in atopic dermatitis patients by the end of 2020 to be confirmatory. The results will support Phase 2 studies powered to show RPT193's efficacy in atopic dermatitis, asthma, and other allergic diseases, contends Jallah, who keeps a Buy rating on Rapt Therapeutics with a $38 price target.

ShowHide Related Items >><<
REGN Regeneron
$559.60 /

+0.23 (+0.04%)

RAPT Rapt Therapeutics
$17.00 /

+0.68 (+4.17%)

RAPT Rapt Therapeutics
$17.00 /

+0.68 (+4.17%)

05/18/20 Cantor Fitzgerald
Rapt Therapeutics initiated with an Overweight at Cantor Fitzgerald
04/13/20
Fly Intel: Top five analyst initiations
04/13/20 Roth Capital
Rapt Therapeutics initiated with a Buy at Roth Capital
02/11/20 UBS
Rapt Therapeutics price target raised to $44 from $31 at UBS
REGN Regeneron
$559.60 /

+0.23 (+0.04%)

05/15/20 Piper Sandler
Ocular Therapeutix early OTX-TKI data encouraging, says Piper Sandler
05/14/20 Piper Sandler
Piper 'incrementally positive' on Regeneron shares after fireside chat
05/06/20 Canaccord
Regeneron price target raised to $630 from $575 at Canaccord
05/06/20 BMO Capital
Regeneron price target raised to $525 from $466 at BMO Capital
REGN Regeneron
$559.60 /

+0.23 (+0.04%)

RAPT Rapt Therapeutics
$17.00 /

+0.68 (+4.17%)

REGN Regeneron
$559.60 /

+0.23 (+0.04%)

REGN Regeneron
$559.60 /

+0.23 (+0.04%)

REGN Regeneron
$559.60 /

+0.23 (+0.04%)

Initiation
Rapt Therapeutics initiated with an Overweight at Cantor Fitzgerald » 16:12
05/18/20
05/18
16:12
05/18/20
16:12
RAPT

Rapt Therapeutics

$16.32 /

+0.79 (+5.09%)

Cantor Fitzgerald analyst…

Cantor Fitzgerald analyst Altheia Young initiated coverage of Rapt Therapeutics with an Overweight rating and $37 price target.

ShowHide Related Items >><<
RAPT Rapt Therapeutics
$16.32 /

+0.79 (+5.09%)

RAPT Rapt Therapeutics
$16.32 /

+0.79 (+5.09%)

04/13/20
Fly Intel: Top five analyst initiations
04/13/20 Roth Capital
Rapt Therapeutics initiated with a Buy at Roth Capital
02/11/20 UBS
Rapt Therapeutics price target raised to $44 from $31 at UBS
11/25/19
Fly Intel: Top five analyst initiations
RAPT Rapt Therapeutics
$16.32 /

+0.79 (+5.09%)

Hot Stocks
Rapt Therapeutics highlights eary results for RTI193 at SID meeting » 08:13
05/15/20
05/15
08:13
05/15/20
08:13
RAPT

Rapt Therapeutics

$14.54 /

-0.45 (-3.00%)

RAPT Therapeutics…

RAPT Therapeutics announced that researchers presented encouraging results from preclinical and healthy volunteer studies for RPT193 at the Society for Investigative Dermatology Meeting. RPT193 is a small molecule, once-daily oral therapy in development for the treatment of atopic dermatitis and other allergic inflammatory diseases. During the session, Laurence Cheng, M.D., Ph.D., Senior Medical Director at RAPT Therapeutics, presented blinded Phase 1a data from healthy volunteer cohorts of an ongoing seamless Phase 1 study showing that once-daily oral dosing of RPT193 for seven days achieved target drug levels and target coverage with an excellent safety profile in healthy volunteers. In addition, Dr. Cheng noted that in multiple preclinical studies of allergic skin inflammation, once-daily dosing of RPT193 demonstrated efficacy and reduction of Th2 cytokines comparable to treatment with currently available biologics that work by blocking interleukin-4 and IL-13, the major drivers of allergic inflammatory disease.

ShowHide Related Items >><<
RAPT Rapt Therapeutics
$14.54 /

-0.45 (-3.00%)

RAPT Rapt Therapeutics
$14.54 /

-0.45 (-3.00%)

04/13/20
Fly Intel: Top five analyst initiations
04/13/20 Roth Capital
Rapt Therapeutics initiated with a Buy at Roth Capital
02/11/20 UBS
Rapt Therapeutics price target raised to $44 from $31 at UBS
11/25/19
Fly Intel: Top five analyst initiations
RAPT Rapt Therapeutics
$14.54 /

-0.45 (-3.00%)

Earnings
Rapt Therapeutics reports Q1 EPS (56c), consensus (43c) » 08:04
05/14/20
05/14
08:04
05/14/20
08:04
RAPT

Rapt Therapeutics

$14.99 /

-0.65 (-4.16%)

Reports Q revenue…

Reports Q revenue $935,000, consensus $4.17M. "We continue to progress our programs during these challenging times. Our first priority is to protect our employees and our patients. We are practicing social distancing in the lab and conducting a good portion of our work remotely," said Brian Wong, M.D., Ph.D., President and CEO of RAPT Therapeutics. "We remain in close contact with investigators from all of our clinical trial sites. As for our FLX475 trial, sites in Asia and some U.S. sites continue to enroll, although there has been some slowing in some regions as investigators adjust to SARS CoV2-related dynamics. We anticipate reporting initial results from our FLX475 Phase 1/2 trial in the second half of 2020. We also are in contact with our RPT193 investigators. We expect to complete enrollment of patients with atopic dermatitis in the Phase 1b portion of our Phase 1 study and report results from the full Phase 1 study by the end of the year."

ShowHide Related Items >><<
RAPT Rapt Therapeutics
$14.99 /

-0.65 (-4.16%)

RAPT Rapt Therapeutics
$14.99 /

-0.65 (-4.16%)

04/13/20
Fly Intel: Top five analyst initiations
04/13/20 Roth Capital
Rapt Therapeutics initiated with a Buy at Roth Capital
02/11/20 UBS
Rapt Therapeutics price target raised to $44 from $31 at UBS
11/25/19
Fly Intel: Top five analyst initiations
Over a quarter ago
Initiation
Fly Intel: Top five analyst initiations » 10:26
04/13/20
04/13
10:26
04/13/20
10:26
RAPT

Rapt Therapeutics

$17.30 /

+0.5 (+2.98%)

, ALLO

Allogene Therapeutics

$22.55 /

-0.12 (-0.53%)

, CARR

Carrier Global

$14.27 /

-0.52 (-3.52%)

, TTGT

TechTarget

$21.58 /

-0.08 (-0.37%)

, NVCN

Neovasc

$1.78 /

+0.12 (+7.23%)

Catch up on today's…

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Rapt Therapeutics (RAPT) initiated with a Buy at Roth Capital. 2. Allogene Therapeutics (ALLO) initiated with a Buy at SunTrust. 3. Carrier Global (CARR) initiated with a Neutral at Citi. 4. TechTarget (TTGT) initiated with a Buy at National Securities. 5. Neovasc (NVCN) initiated with an Outperform at Noble Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
RAPT Rapt Therapeutics
$17.30 /

+0.5 (+2.98%)

04/13/20 Roth Capital
Rapt Therapeutics initiated with a Buy at Roth Capital
02/11/20 UBS
Rapt Therapeutics price target raised to $44 from $31 at UBS
11/25/19
Fly Intel: Top five analyst initiations
11/25/19 UBS
Rapt Therapeutics initiated with a Buy at UBS
ALLO Allogene Therapeutics
$22.55 /

-0.12 (-0.53%)

04/13/20 Truist
Allogene Therapeutics initiated with a Buy at SunTrust
04/13/20 Truist
Allogene Therapeutics initiated with a Buy at SunTrust
03/27/20 Roth Capital
Allogene seeing ALL trial disruption from COVID-19, says Roth Capital
03/04/20 Stifel
Allogene Therapeutics initiated with a Hold at Stifel
CARR Carrier Global
$14.27 /

-0.52 (-3.52%)

04/13/20 Citi
Carrier Global initiated with a Neutral at Citi
04/09/20
Fly Intel: Top five analyst initiations
04/09/20 Morgan Stanley
Carrier Global initiated with an Equal Weight at Morgan Stanley
04/09/20 Barclays
Carrier Global initiated with an Equal Weight at Barclays
TTGT TechTarget
$21.58 /

-0.08 (-0.37%)

04/13/20 National Securities
TechTarget initiated with a Buy at National Securities
11/07/19 Lake Street
TechTarget price target raised to $29 from $24 at Lake Street
05/09/19 Lake Street
TechTarget target raised to $24 after Q1 upside at Lake Street
05/09/19 Craig-Hallum
TechTarget upgraded to Buy from Hold at Craig-Hallum
NVCN Neovasc
$1.78 /

+0.12 (+7.23%)

04/13/20 Noble Capital
Neovasc initiated with an Outperform at Noble Capital
10/24/19 H.C. Wainwright
Neovasc initiated with a Buy at H.C. Wainwright

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.